Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a hold rating to a buy rating in a research note published on Thursday. They currently have $8.25 price target on the biopharmaceutical company’s stock.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
A number of other research firms have also commented on DERM. ValuEngine upgraded shares of Dermira from a strong sell rating to a sell rating in a research note on Tuesday, October 2nd. Cantor Fitzgerald reiterated a buy rating and set a $20.00 price target on shares of Dermira in a research note on Wednesday, November 7th. BidaskClub upgraded shares of Dermira from a buy rating to a strong-buy rating in a research note on Thursday, October 4th. Mizuho reiterated a hold rating and set a $10.00 price target on shares of Dermira in a research note on Tuesday, October 2nd. Finally, Guggenheim reiterated a buy rating and set a $20.00 price target on shares of Dermira in a research note on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $21.04.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.05. The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.80 million. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. Research analysts predict that Dermira will post -5.2 earnings per share for the current year.
In other Dermira news, Director Matthew K. Fust sold 4,000 shares of the company’s stock in a transaction dated Friday, October 19th. The shares were sold at an average price of $13.75, for a total transaction of $55,000.00. Following the transaction, the director now directly owns 14,051 shares in the company, valued at $193,201.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 14.80% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace North America L.P. acquired a new position in Dermira during the third quarter worth about $128,000. grace capital acquired a new position in Dermira during the second quarter worth about $153,000. AQR Capital Management LLC acquired a new position in Dermira during the third quarter worth about $211,000. First Republic Investment Management Inc. acquired a new position in Dermira during the second quarter worth about $221,000. Finally, MetLife Investment Advisors LLC grew its position in Dermira by 55.6% during the third quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 10,085 shares during the period. Institutional investors own 84.90% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Recommended Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.